AI assistant
Sending…
Compass Therapeutics, Inc. — Director's Dealing 2023
Feb 9, 2023
32588_dirs_2023-02-09_1b35f3e4-a2cc-4db7-8fc8-a093a2275301.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2023-02-08
Reporting Person: Ferneau Philip (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-08 | Stock Option (Right to Buy) | $3.93 | A | 50000 | Acquired | 2033-02-07 | Common Stock (50000) | Direct |
Footnotes
F1: The options vest over 48 substantially equal monthly installments starting March 8, 2023.
More from Compass Therapeutics, Inc.
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
May 5
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 27
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Jan 12
Regulatory Filings
2026
Jan 8
Regulatory Filings
2026
Jan 6
Director's Dealing
2026
Jan 5